Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06819293
PHASE1

IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma

Sponsor: Grit Biotechnology

View on ClinicalTrials.gov

Summary

This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma

Official title: A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2024-12-06

Completion Date

2027-12-07

Last Updated

2025-02-17

Healthy Volunteers

No

Interventions

BIOLOGICAL

IB-T101 injection

IB-T101 injection to treat advanced clear renal cell carcinoma

Locations (1)

Tongji hospital, Huazhong University of Science and Technology

Wuhan, Hubei, China